![ESMO-Immuno-Oncology-2023_Audience_02](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-immuno-oncology-2023/esmo-immuno-oncology-2023_audience_02/18674474-1-eng-GB/esmo-immuno-oncology-2023_audience_02_i770.jpg)
TILs show long-term efficacy in melanoma, but predicting treatment response is still a challenge
After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.